Vertex Presents Data Highlighting ALYFTREK’s Superiority In Treating Cystic Fibrosis Shows Positive Outcomes And Quality of Life

Vertex Pharmaceuticals has announced new data reinforcing the clinical and quality-of-life benefits of its cystic fibrosis (CF) therapies, particularly highlighting the impact of ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor). Already approved in the U.S. and U.K., ALYFTREK is under review in several major markets including the EU, Canada, Australia, New Zealand, and Switzerland. The findings were presented during a major scientific conference showcasing data from multiple CFTR modulator studies.

“These new data further demonstrate that reducing sweat chloride via treatment with CFTR modulators drives improved CFTR function and may ultimately result in better outcomes for patients across a variety of measures. Importantly, the data also indicate that ALYFTREK, which has been shown to deliver even greater reductions in sweat chloride than TRIKAFTA, may drive improved quality of life and other health-related outcomes above and beyond even what we’ve seen with CFTR modulators to date,” said Professor Isabelle Fajac, Pulmonologist, Professor of Physiology at APHP-Université Paris Cité, Paris, France. 

A pooled analysis of Vertex’s CFTR modulators, including ALYFTREK, revealed that a reduction in sweat chloride (SwCl) levels, a biomarker of restored CFTR function, correlates with improved clinical outcomes in CF patients. Participants with SwCl levels below 60 mmol/L saw significant improvements in lung function, reduced pulmonary exacerbations, better nutrition, and higher quality of life. The benefits were even more pronounced among patients whose SwCl dropped below 30 mmol/L.

Furthermore, an examination performed after the Phase 3 trials showed ALYFTREK helps patients experience better health-related quality of life measures than TRIKAFTA®. Children between the ages of 6 and 11 also experienced these positive improvements. This information shows potential for ALYFTREK to become a leading therapy that can help patients with CF symptoms and enhance everyday functioning.